Noa Sabag
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Noa Sabag has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Yakobson
The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer-Sheva 8410501, Israel
1 shared publication - Eldad Silberstein
Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be’er Sheva 84101, Israel
1 shared publication - Meir Retchkiman
Department of Plastic Surgery, Shaare Zedek Medical Center, Jerusalem, Israel
1 shared publication
Latest Publications
- Open Access
- 1 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11656
Novel Biomarkers and Therapeutic Targets for Melanoma
Malignant melanoma is one of the most common cancers in the world. In the disease’s early stages, treatment involves surgery, in advanced stages however, treatment options were once scarce. There has been a paradigm shift in advanced melanoma treatment with the introduction of immunotherapy and targeted therapies. Understanding the molecular pathways and their pathologic counterparts helped identifying specific biomarkers that lead to the development of specific targeted therapies. In this review we briefly present some of these markers and their relevance to melanoma treatment.
- 1 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11656
Open AccessNovel Biomarkers and Therapeutic Targets for Melanoma
Malignant melanoma is one of the most common cancers in the world. In the disease’s early stages, treatment involves surgery, in advanced stages however, treatment options were once scarce. There has been a paradigm shift in advanced melanoma treatment with the introduction of immunotherapy and targeted therapies. Understanding the molecular pathways and their pathologic counterparts helped identifying specific biomarkers that lead to the development of specific targeted therapies. In this review we briefly present some of these markers and their relevance to melanoma treatment.